Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566)
Hong Kong · Delayed Price · Currency is HKD 5.34
+0.09 (1.71%)
Aug 27, 2026, 1:56 PM HKT
HKG:2566 Revenue
Hangzhou Jiuyuan Genetic Biopharmaceutical had revenue of 630.95M CNY in the half year ending June 30, 2026, a decrease of -10.17%. This brings the company's revenue in the last twelve months to 1.30B, down -0.55% year-over-year. In the year 2025, Hangzhou Jiuyuan Genetic Biopharmaceutical had annual revenue of 1.31B, down -4.59%.
Revenue (ttm)
1.30B CNY
Revenue Growth
-0.55%
P/S Ratio
0.84
Revenue / Employee
723.79K CNY
Employees
1,794
Market Cap
1.26B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.31B | -62.88M | -4.59% |
| Dec 31, 2024 | 1.37B | 81.78M | 6.35% |
| Dec 31, 2023 | 1.29B | 162.00M | 14.40% |
| Dec 31, 2022 | 1.13B | -181.85M | -13.91% |
| Dec 31, 2021 | 1.31B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Mabpharm | 718.98M |
| Guangzhou Innogen Pharmaceutical Group | 176.96M |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 171.70M |
| CANbridge Pharmaceuticals | 55.62M |
| Beijing Biostar Pharmaceuticals | 37.13M |
| Kintor Pharmaceutical | 36.37M |
| Zhaoke Ophthalmology | 35.58M |
| SinoMab BioScience | 6.28M |